Synergistic changes in bystander CD8 and conventional CD4 T cells during neoadjuvant chemoimmunotherapy for non-small cell lung cancer reveal treatment response
Alterations in specific CD8<sup>+</sup> and CD4<sup>+</sup> T-cell subpopulations during neoadjuvant chemoimmunotherapy may favor better outcomes and are potentially associated with tumor hypoxia. These findings provide a new perspective on developing strategies to improve treatment sensitivity in non-small cell lung cancer.
Authors
- Liying Yang (ORCID: https://orcid.org/0000-0003-1442-4915)
- Qianhui Chen (ORCID: https://orcid.org/0009-0002-6651-9684)
- Xiaorong Sun (ORCID: https://orcid.org/0000-0001-8520-9556)
- Jian Sun (ORCID: https://orcid.org/0000-0003-1569-0334)
- Feng Cao (ORCID: https://orcid.org/0000-0002-1010-6429)
- Jiaxiao Geng
- Yushan Yan (ORCID: https://orcid.org/0000-0001-6616-4575)
- Li Wu (ORCID: https://orcid.org/0009-0003-9642-3883)
- Hao Yang (ORCID: https://orcid.org/0000-0003-0548-3040)
- Ligang Xing (ORCID: https://orcid.org/0000-0002-9146-3048)
- Miaoqing Zhao
Institutions
- Shandong University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Pathology & Oncology Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.3389/pore.2025.1612229
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Science and Technology Major Project